title: Zoledronic Acid Treatment in Primary Bone Marrow Edema Syndrome.
abstract: Primary bone marrow edema syndrome (BMES) is characterized by the combination of joint pain and distinctive magnetic resonance imaging changes. It has been suggested that the use of bisphosphonate drugs reduce symptom severity. Our objective was to review cases of patients diagnosed with BMES in the last 7 years who had been treated with zoledronic acid. Access to a pharmaceutical database was gained in order to obtain a list of zoledronic acid prescriptions. Based on clinical and MRI criteria for BMES, patients were selected. Baseline pain intensity was evaluated on a scale of 0 to 3 and was also assessed after 3 and 12 months. Functional recovery was evaluated by noting if a patient had returned to carrying out his or her normal daily activities. Out of 633 patients, 17 cases of BMES were identified (8 men), with a median age of 54 ± 14.1 years. The most frequently affected joint was the ankle (9), followed by the hip. Sixteen patients presented with moderate to severe pain initially. Of those patients, 13 had no pain after 12 months. Zoledronic acid is a option in the management of BMES, since 75% of patients treated with it presented with a complete response.
authors.forename: Bryan Josué
authors.initials: BJ
authors.lastname: Flores-Robles
authors.forename: Jesus
authors.initials: J
authors.lastname: Sanz-Sanz
authors.forename: Adel Abel
authors.initials: AA
authors.lastname: Sanabria-Sanchinel
authors.forename: Dixie
authors.initials: D
authors.lastname: Huntley-Pascual
authors.forename: José Luis
authors.initials: JL
authors.lastname: Andréu Sánchez
authors.forename: José
authors.initials: J
authors.lastname: Campos Esteban
authors.forename: Ricardo
authors.initials: R
authors.lastname: Blanco
authors.forename: Carolina
authors.initials: C
authors.lastname: Merino-Argumanez
authors.forename: Maria
authors.initials: M
authors.lastname: Espinosa-Malpartida
authors.forename: Maria Consuleo
authors.initials: MC
authors.lastname: Ramos-Giráldez
authors.forename: Hildegarde
authors.initials: H
authors.lastname: Godoy-Tundidor
authors.forename: Maria Mercedes
authors.initials: MM
authors.lastname: Jiménez-Palop
authors.forename: Carmen
authors.initials: C
authors.lastname: Barbadillo Mateos
authors.forename: Luis Fernando
authors.initials: LF
authors.lastname: Villa-Alcázar
authors.forename: Carlos Maria
authors.initials: CM
authors.lastname: Isasi
authors.forename: Juan Bartolome
authors.initials: JB
authors.lastname: Mulero
mesh_terms: D000328:Adult; D000368:Aged; D018771:Arthralgia / Q000188:drug therapy*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001853:Bone Marrow / Q000187:drug effects*; D016208:Databases, Factual; D004164:Diphosphonates / Q000627:therapeutic use*; D004487:Edema / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013577:Syndrome; D000077211:Zoledronic Acid
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid
keywords: bisphosphonate; bone marrow edema; joint pain; primary bone marrow edema syndrome; transient osteoporosis; zoledronic acid